ONCOLOGY Staff

Joshua Richter, MD, discusses the optimal use of selinexor in the treatment of relapsed/refractory multiple myeloma.

An expert panel highlights novel therapeutic approaches for newly diagnosed and relapsed multiple myeloma.

“Upon activating a fluorescent lamp, the cancer tissue glows very brightly, like stars against a black sky, and enables us to see exactly where the tumor tissue was.”

Based on several patient cases, expert oncologists review the evolving treatment landscape of HER2+ breast cancer with a focus on brain metastases.

Experts from the Mayo Clinic and Moffitt Cancer Center go head-to-head to discuss recent data in multiple myeloma and updates from recent meetings.

Experts discuss updates in HR+ breast cancer, with a focus on treatment options before and after progression and emerging data.

Breast cancer experts discuss the latest research into the treatment of HER2+ metastatic breast cancer with brain metastases and how new data may affect decision-making in 3 patient cases.

Expert hematologist-oncologists review the clinical data on the long-term use of tagraxofusp and share their real-world experiences.

Expert oncologists review key updates regarding metastatic colorectal cancer from recent meetings and discuss their implications on real-world clinical practice.

Experts discuss the genetics of multiple myeloma, the prevalent testing paradigms in this space, and possibilities for the future.

Expert oncologists review the clinical data supporting the use of sacituzumab govitecan in metastatic triple-negative breast cancer.

Experts review key clinical data and current treatment strategies for renal cell carcinoma following updates from the 2022 IKCS meeting.

“You have to be on your game continually, you have to continually self-evaluate, and the field moves quickly.”

Elle Charnisky, a patient with stage IV HER2+ metastatic colorectal cancer (mCRC), joins a panel of healthcare professionals to discuss how HER2 alternations are detected and how patients with HER2+ mCRC are optimally treated to improve outcomes.

Expert hematologist-oncologists discuess the E7438-G000-101 clinical trial and consider the EZH2 inhibitor tazemetostat as a treatment for relapsed/refractory follicular lymphoma.

Experts from leading institutions debate the latest advances in multiple myeloma.

Joseph Mikhael, MD, and Hakan Kaya, MD, review key efficacy and safety data for the combination of selinexor, carfilzomib, and dexamethasone in R/R MM and discuss optimal dosing and adverse event management strategies for selinexor.

Centering discussion on clinical scenarios of urothelial carcinoma, expert oncologists review recent data and discuss how patient care is evolving.

Two teams from leading institutions go head-to-head to debate the latest datasets and advances in chronic myeloid leukemia (CML).

Martin Dietrich, MD, PhD, Sara Tolaney, MD, MPH, and Gregory Vidal, MD, PhD review recent data from the TROPiCS-02 trial on sacituzumab govitecan and discuss the clinical implications of these findings.

In a recent Between the Lines, Joshua Richter, MD, and Peter Forsberg, MD, discussed a recent commentary on weekly dosing and supportive care solutions for selinexor in patients with multiple myeloma, and provided a general overview of the agent in this treatment landscape.

A panel of experts in multiple myeloma discusses recent data updates from 2022 International Myeloma Society Annual Meeting and how it influences treatment strategies in clinical practice.

At an Around the Practice program in Charlotte, NC, experts spoke about the most recent research in multiple myeloma.

Expert oncologists review clinical scenarios to define best treatment practices for patients with EGFR-mutated non–small cell lung cancer.

Centering discussion on two clinical scenarios, expert panelists review recent evolutions in the field of graft-vs-host disease management and provide their perspective on optimal treatment strategies.

One of the CRESTONE investigators, Tejas Patil, MD, assistant professor of medicine–medical oncology at the University of Colorado School of Medicine in Aurora, discussed seribantumab in previously treated patients with NRG1 fusion–positive tumors.

Expert oncologists review key studies in the metastatic castration-resistant prostate cancer treatment landscape and discuss how evidence can be applied to clinical practice to improve patient outcomes.

“Opportunities to escalate therapies that work well in stage IV into what we consider a more curative setting...are exactly what we need to be looking for.” –Mark A. Socinski, MD

A panel of experts review real-world clinical scenarios to highlight recent advances in the management of multiple myeloma.

Michael R. Bishop, MD, and Bruce B. Bank, MD, review results from the ELEVATE-RR noninferiority trial on acalabrutinib versus ibrutinib in CLL, and discuss the clinical implications of the findings.